Study of Offspring of Women With Type 1 Diabetes (EPICOM)
|ClinicalTrials.gov Identifier: NCT01559181|
Recruitment Status : Unknown
Verified October 2015 by Zuzana Vlachová, MD, Odense University Hospital.
Recruitment status was: Active, not recruiting
First Posted : March 21, 2012
Last Update Posted : October 14, 2015
|First Submitted Date||March 19, 2012|
|First Posted Date||March 21, 2012|
|Last Update Posted Date||October 14, 2015|
|Study Start Date||April 2012|
|Actual Primary Completion Date||April 2015 (Final data collection date for primary outcome measure)|
|Current Primary Outcome Measures
|Original Primary Outcome Measures||Same as current|
|Change History||Complete list of historical versions of study NCT01559181 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures
|Original Secondary Outcome Measures||Same as current|
|Current Other Outcome Measures||Not Provided|
|Original Other Outcome Measures||Not Provided|
|Brief Title||Study of Offspring of Women With Type 1 Diabetes|
|Official Title||Environmental Versus Genetic and Epigenetic Influences on Growth, Metabolism and Cognitive Function in Offspring of Mothers With Type 1 Diabetes|
There is an increasing trend in the society for developing obesity, type 2 diabetes and cardiovascular diseases. It is therefore important to identify the risk factors behind this tendency. Recent studies have shown that exposure to high blood sugar levels in pregnancy (as in mothers with type 1 diabetes) may play a role in the development of obesity, type 2 diabetes and cardiovascular diseases later in life for the children. Some studies suggest that high blood sugar levels during pregnancy can also affects cognitive function as well as growth and development of puberty. The mechanisms behind this are not sufficiently clarified yet.
In the period 1993-1999, pregnant women with type 1 diabetes in Denmark were followed and information about the course of pregnancy was collected, including the long-term blood sugar level during pregnancy and the children's' condition at birth. The unique opportunities in Denmark to identify and follow the children of these mothers and the possibility to select a comparison group of children of non-diabetic mothers gives a unique opportunity to examine the children of mothers with type 1 diabetes and accurately investigate the effect of blood sugar levels in pregnancy on conditions later in life.
There has not previously been made any study of this size and it is the investigators hope to be able to quantify the effect of blood sugar level during pregnancy on outcomes later in life. This will potentially give the possibility to detect individuals at risk for cardiovascular diseases earlier and to improve prevention targets in children of mothers with diabetes.
Health conditions result from a combination of genetic susceptibility and environmental influences. While the genotype is determined at conception the phenotype is modulated and influenced by environmental and epigenetic factors throughout life, not only postnatally but already in uteri and possibly even at preimplantation stages.
Recent studies have highlighted the possible role of intrauterine exposure to maternal diabetes in the pathogenesis of overweight, type 2 diabetes and cardiovascular disease. A hyperglycaemic intrauterine environment may also affect cognitive function, childhood growth and pubertal development in the offspring. During 1993-99 all pregnancies in women with pre-gestational type 1 diabetes were prospectively reported to a national registry in the Danish Diabetes Association. This nationwide registry contain detailed information of maternal demography, pregnancy outcome and diabetes status including glycated haemoglobin (HbA1c) in a prospective cohort of 900 women and their newborn offspring. These data are therefore ideal for a large-scale study on long-term effects of a diabetic intrauterine environment.
The study consists of 3 substudies.
To study long-term effects of a diabetic intrauterine environment in offspring of women with type 1 diabetes compared to matched controls from the background population with respect to:
B) To study if HbA1c-level in pregnancy is an independent predictor of these outcomes within the study group.
To study differences in offspring of women with type 1 diabetes compared to offspring from the background population with respect to:
To study differences in offspring of women with type 1 diabetes compared to compared to matched controls from the background population without a family history of diabetes with respect to:
A) State-of-the-art metabolic characterization using euglycemic-hyperinsulinemic clamp
B) DNA methylation, RNA transcription and protein quantification in muscle and adipose-tissue
The study is a prospective follow-up study. The study group includes the offspring of women with type 1 diabetes from the national diabetes birth registry (1993-99, n=900) with information of HbA1c prior to conception and/or 1st trimester HbA1c and a control group including offspring of women without diabetes who delivered during the same period matched with respect to gender and age of offspring and the family's postcode as an indirect marker of the socioeconomic background.
Material and Methods
Clinical characteristics at the time of exposure:
Study group (diabetes-exposed):
The following data were reported to the national diabetes birth registry:
Control group Maternal age, parity, height, pre-gestational weight, information on preeclampsia, gestational age, birth weight and neonatal morbidity will be collected from medical records.
Examination program at follow-up:
Study I: Clinical study (450 diabetes-exposed and 450 controls aged 13-19 years) Clinical examination to determine the effect of intrauterine hyperglycaemia on growth, pubertal development, metabolism and cognitive function in childhood.
The participants meet fasting in the morning. The following examinations will be performed:
Growth and pubertal development:
Cognitive examination including:
The children and their parents will be asked to fill in a questionnaire addressing psychosocial aspects, demographics (height, weight) and history of menstrual cycle. Furthermore, the children will be asked to fill in a questionnaire on Self-reported physical activity (IPAQ-questionnaire).
Study II: Register-based study (n=900 diabetes-exposed; for every case we will sex and age match 100 controls, resulting in n=90,000 controls aged 12-18 years) A register-based study will be performed to determine the effect of intrauterine hyperglycaemia on congenital malformations, morbidity and mortality in childhood.
Study population In the cohort of 900 children from the national diabetes birth cohort, we will study all subjects utilizing register data concerning morbidity, mortality and use of prescription medicine. For every diabetes-exposed person Statistics Denmark will identify 100 age, sex and calendar-time matched controls from the background population from the Central Person Register (Statistics Denmark).
Morbidity and mortality - Operational strategy
Endpoints Morbidity: diabetes-exposed vs. controls from the background population Medical treatment: diabetes-exposed vs. controls from the background population Mortality: diabetes-exposed vs. controls from the background population
Statistics Incidence rates will be calculated as new cases per 100.000 per year and analyzed by Poisson regression. Via Statistics Denmark controls will be identified and matched appropriately.
Morbidity and mortality will be analyzed by the Kaplan-Meier statistic, with log-rank test and Cox regression with relevant covariates.
Study III: Sub-study (n=50 diabetes-exposed and n=50 un-exposed controls aged 18-19 years) Offspring of mothers with type 1 diabetes, born before 1 January 1994 (over 18 years of age at the date of invitation), and who participated in the study A will be invited to participate in study B. Study B is anticipated to involve approximately 50 diabetes-exposed and approximately 50 un-exposed controls 18 - 19 years of age at time of examination. The study groups will be matched according to BMI, gender, date of birth and level of physical activity. All participants should be drug-naive and healthy with a BMI between 20 and 30, and controls should have no family history of diabetes. Since all participants will be over the age of 18, they will be able to provide informed written consent.
The selected subgroup of offspring of mothers with type 1 diabetes and matched controls will be investigated by state-of-the-art metabolic characterization using euglycemic-hyperinsulinemic clamp with tracer glucose combined with indirect calorimetry allowing reliable estimates of whole-body glucose disposal rates, endogenous glucose production and glucose and lipid oxidation. Moreover assessment of physical activity level using the IPAQ-questionnaire will be complemented by studies of maximal oxygen consumption (VO2max). During the clamp studies, tissue biopsies from subcutaneous abdominal fat and thigh muscle (m. vastus lateralis) will be obtained for studies of potential long-term molecular consequences of intrauterine exposure to hyperglycemia - metabolic memory of birth. This will include application of several discovery-mode (hypothesis free), global approaches such as transcriptional profiling using microarray-based technologies, quantitative proteomics, bioinformatics including pathway analysis and subsequent validation of observed abnormalities using qRT-PCR, immunoblotting and other more classical protein technologies.
Physical activity (Day 1)
The children and their parents will be asked to fill in a questionnaire addressing psychosocial and demographic aspects and self-reported physical activity (IPAQ-questionnaire). VO2-max is determined by a graded maximal test (VO2-peak) on a cycle ergometer using indirect calorimetry.
State-of-the-art metabolic characterization (Day 2):
Euglycemic-hyperinsulinemic clamp Subjects are admitted after a 12-h overnight fast to the centre at Odense University Hospital. They are instructed to consume a standardized diet, and to refrain from physical activity for 48-h before the experiments. The study subjects are examined by a euglycemic-hyperinsulinemic clamp (insulin 40mU/min/m2 for 4-h) using tracer technology as described55. The studies are combined with indirect calorimetry allowing estimates of glucose disposal rates, endogenous glucose production, glucose and lipid oxidation, and non-oxidative glucose metabolism as described. Blood samples are drawn every 20 min during the clamp for assessment of plasma glucose, FFA, adipokines, and serum insulin and C-peptide. During the basal and insulin-stimulated states, tissue biopsies are taken from m. vastus lateralis and subcutaneous abdominal fat using a modified Bergstrom needle with suction under local anesthesia. Each biopsy is rapidly frozen in liquid nitrogen within 30 s and stored at -130°C for later analysis as described below. Body fat (%) is determined by the bioimpedance method.
Transcriptomics and proteomic analysis of skeletal muscle and adipose tissue include:
Microarray-based transcriptional profiling and biological pathway analysis:
Discovery-mode quantitative proteomics of tissue biopsies:
Targeted quantitative proteomics:
Analysis of DNA methylation
Whole genome methylation analysis
Methylation-Sensitive High Resolution Melting analysis (MS-HRM)
Gene Expression Analysis
Statistical Analysis Mann-Whitney U test will be used to assess for each CpG, whether two groups had the same distribution of methylation. To eliminate probes that did not work and other diverging values, beta values in each group will be trimmed for extremes prior to the calculation of the average beta value. Next, only genes with the highest 5% tail of the absolute average beta value differences between the two groups will be selected. Thus CpGs with a p-value below 0.005 and with the highest beta value differences between the two groups will be used for identification of genes with statistically significant diabetes-specific changes in methylation. Comparison of array methylation results with MS-HRM results will be performed with a Mann-Whitney U test and a Chi2 test for trend. Spearman coefficients will be calculated to assess the correlation between methylation and gene expression.
Novelty and importance
The rapidly increasing burden of overweight and cardiovascular disease is becoming a threat to both the individual and global economy. It is therefore essential to identify risk groups to target preventive strategies. Exposure to intrauterine hyperglycemia contributes to the epidemic through a vicious-cycle passing increased susceptibility on to the next generation via pathways that are only sparsely understood.
This study includes a very large cohort of diabetes-exposed offspring of well-characterized prospectively studied women with type 1 diabetes. It includes information on maternal glycemia during pregnancy, which is imperative to assess possible associations with estimates of offspring metabolism and cognitive function. The register-based study is unique and enables collection of information on morbidity and mortality in the whole cohort. The specific molecular signature of intrauterine exposure to hyperglycemia in human tissues has to our knowledge not been examined before, and although the above-mentioned studies suggest the possible involvement of certain pathways in skeletal muscle and adipose tissue, it is important to investigate the metabolic memory of birth using hypothesis-free, discovery-mode global approaches to discover potential perturbations in both expected and unexpected pathways.
|Study Design||Observational Model: Case Control
Time Perspective: Prospective
|Target Follow-Up Duration||Not Provided|
|Biospecimen||Retention: Samples With DNA
Whole blood, serum and plasma. Tissue biopsies from m. vastus lateralis and subcutaneous abdominal fat (only selected subgroup of participants)
|Sampling Method||Probability Sample|
|Study Population||Offspring of mothers with type one diabetes.|
|Condition||Type 1 Diabetes|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status||Unknown status|
|Original Estimated Enrollment
|Estimated Study Completion Date||December 2016|
|Actual Primary Completion Date||April 2015 (Final data collection date for primary outcome measure)|
|Ages||13 Years to 19 Years (Child, Adult)|
|Accepts Healthy Volunteers||No|
|Contacts||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries||Denmark|
|Removed Location Countries|
|Other Study ID Numbers||2011-41-6044|
|Has Data Monitoring Committee||No|
|U.S. FDA-regulated Product||Not Provided|
|IPD Sharing Statement||Not Provided|
|Responsible Party||Zuzana Vlachová, MD, Odense University Hospital|
|Study Sponsor||Odense University Hospital|
|PRS Account||Odense University Hospital|
|Verification Date||October 2015|